Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MGNX
stocks logo

MGNX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
27.81M
+43.69%
-0.290
+15.84%
9.27M
-29.76%
-0.632
-2.73%
9.27M
-58.34%
-0.635
+11.36%
Estimates Revision
The market is revising Upward the revenue expectations for MacroGenics, Inc. (MGNX) for FY2025, with the revenue forecasts being adjusted by 53.76% over the past three months. During the same period, the stock price has changed by -31.00%.
Revenue Estimates for FY2025
Revise Upward
up Image
+53.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-39.43%
In Past 3 Month
Stock Price
Go Down
down Image
-31.00%
In Past 3 Month
Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 1.380
sliders
Low
2.00
Averages
3.00
High
4.00
Current: 1.380
sliders
Low
2.00
Averages
3.00
High
4.00
Barclays
NULL -> Overweight
initiated
$3
2025-09-16
Reason
Barclays
Price Target
$3
2025-09-16
initiated
NULL -> Overweight
Reason
Barclays initiated coverage of MacroGenics with an Overweight rating and $3 price target.
Barclays
Etzer Darout
Overweight
initiated
$3
2025-09-16
Reason
Barclays
Etzer Darout
Price Target
$3
2025-09-16
initiated
Overweight
Reason
Barclays analyst Etzer Darout assumed coverage of MacroGenics with an Overweight rating and $3 price target. The firm believes MGC026 could drive share upside in 2026 due to the shortcomings of the competitor B7H3 antibody drug conjugate programs.
Leerink
Outperform
to
NULL
downgrade
$8 -> $5
2025-08-15
Reason
Leerink
Price Target
$8 -> $5
2025-08-15
downgrade
Outperform
to
NULL
Reason
Leerink lowered the firm's price target on MacroGenics to $5 from $8 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 financial results that were largely in line and notably announced the appointment of Eric Risser as President and CEO the day before. Overall, Leerink's thesis on MacroGenics is based on potential royalties and milestone payments related to multiple partnered programs and cash.
B. Riley
B. Riley
Neutral
downgrade
$5 -> $3
2025-05-20
Reason
B. Riley
B. Riley
Price Target
$5 -> $3
2025-05-20
downgrade
Neutral
Reason
B. Riley lowered the firm's price target on MacroGenics to $3 from $5 and keeps a Neutral rating on the shares. The company's key operational updates on a more focused oncology pipeline were noted on its earnings call, with management reaffirming guidance for disclosure of two key trial readouts in 2025, the analyst tells investors in a research note. B. Riley believes the end of selling pressure in the follow-up to the string of vobra duo-related disappointments may be nearing.
Barclays
Peter Lawson
Overweight
downgrade
$8 -> $3
2025-05-14
Reason
Barclays
Peter Lawson
Price Target
$8 -> $3
2025-05-14
downgrade
Overweight
Reason
Barclays analyst Peter Lawson lowered the firm's price target on MacroGenics to $3 from $8 and keeps an Overweight rating on the shares post the earnings report. The firm de-risked the model to reflect the current market environment.
Stifel
Hold
downgrade
$6 -> $5
2025-05-14
Reason
Stifel
Price Target
$6 -> $5
2025-05-14
downgrade
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for MacroGenics Inc (MGNX.O) is -0.64, compared to its 5-year average forward P/E of -3.50. For a more detailed relative valuation and DCF analysis to assess MacroGenics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.50
Current PE
-0.64
Overvalued PE
1.69
Undervalued PE
-8.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.21
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.67
Undervalued EV/EBITDA
-7.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.07
Current PS
0.00
Overvalued PS
9.38
Undervalued PS
0.76
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MGNX News & Events

Events Timeline

(ET)
2025-11-12
16:16:12
MacroGenics anticipates sufficient cash to sustain operations through late 2027.
select
2025-11-12
16:15:45
MacroGenics Announces Q3 EPS of 27 Cents Compared to 90 Cents Last Year
select
2025-08-14 (ET)
2025-08-14
16:05:31
MacroGenics reports Q2 EPS (57c), consensus (38c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-13NASDAQ.COM
After-Hours Movers: MGNX, SLS, KRMD, HYPR, WVE Experience Significant Changes After Q3 Reports

  • MacroGenics Earnings Report: MacroGenics, Inc. saw a 10.2% increase in after-hours trading, reporting a third-quarter net income of $16.8 million, down from $56.3 million year-over-year, with revenue falling to $72.8 million.

  • SELLAS Life Sciences Update: SELLAS Life Sciences Group, Inc. rose 9.4% after narrowing its quarterly net loss to $6.8 million, with cash and equivalents reported at approximately $44.3 million as of September 30, 2025.

  • KORU Medical Systems Performance: KORU Medical Systems, Inc. gained 8.47% after reporting a narrower net loss of $0.8 million and a 27.2% revenue increase to $10.4 million, while raising its full-year revenue guidance.

  • Wave Life Sciences Results: Wave Life Sciences Ltd. increased by 5.68% after reporting a third-quarter net loss of $53.9 million, an improvement from the previous year, with revenue of $7.6 million.

[object Object]
Preview
9.5
08-15NASDAQ.COM
MacroGenics Revenue Doubles in Q2

  • Financial Performance: MacroGenics reported Q2 2025 GAAP revenue of $22.2 million, significantly below the $31.7 million analyst estimate, with a loss per share of $(0.57), missing expectations as well. The company highlighted lower operating costs but faced challenges due to the absence of product sales after exiting its previous marketed product.

  • Strategic Focus and Pipeline: The company is shifting its focus to research-stage pipeline candidates, emphasizing partnerships and cost management while maintaining sufficient funds through mid-2027. Key upcoming milestones include clinical results for its lead candidate lorigerlimab and potential regulatory approvals for collaborations that could yield significant payments.

[object Object]
Preview
9.5
08-13NASDAQ.COM
OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

  • Quarterly Performance: OrganiGram reported a quarterly loss of $0.03 per share, missing the Zacks Consensus Estimate of a loss of $0.01, while revenues reached $51.16 million, exceeding expectations and showing significant year-over-year growth.

  • Market Outlook: The company's stock has underperformed compared to the S&P 500 this year, with a mixed earnings estimate revision trend leading to a Zacks Rank #3 (Hold), indicating expected performance in line with the market moving forward.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is MacroGenics Inc (MGNX) stock price today?

The current price of MGNX is 1.38 USD — it has decreased -1.43 % in the last trading day.

arrow icon

What is MacroGenics Inc (MGNX)'s business?

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

arrow icon

What is the price predicton of MGNX Stock?

Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is MacroGenics Inc (MGNX)'s revenue for the last quarter?

MacroGenics Inc revenue for the last quarter amounts to 72.84M USD, decreased -34.21 % YoY.

arrow icon

What is MacroGenics Inc (MGNX)'s earnings per share (EPS) for the last quarter?

MacroGenics Inc. EPS for the last quarter amounts to 0.27 USD, decreased -70.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for MacroGenics Inc (MGNX)'s fundamentals?

The market is revising Upward the revenue expectations for MacroGenics, Inc. (MGNX) for FY2025, with the revenue forecasts being adjusted by 53.76% over the past three months. During the same period, the stock price has changed by -31.00%.
arrow icon

How many employees does MacroGenics Inc (MGNX). have?

MacroGenics Inc (MGNX) has 341 emplpoyees as of December 05 2025.

arrow icon

What is MacroGenics Inc (MGNX) market cap?

Today MGNX has the market capitalization of 87.30M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free